spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  NCCN 

 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 31 Mar 2020
Caris Life Sciences Launches MI FOLFOXai, Improving Overall Survival by 50% for Metastatic Colorectal Cancer Patients
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 24 Mar 2020
NCCN Guidelines Designate Decipher Prostate as "Recommended" for Men with Adverse Pathology after Radical Prostatectomy
Diagnostics Urology Oncology
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Dec 2019
ArcherDX Announces Close of $55 Million Series C Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jul 2019
RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer
Diagnostics Personnel
 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Mar 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Urology Oncology
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Oct 2018
Agendia Announces Level 1 Inclusion of MammaPrint(R) Breast Cancer Test in Updated National Comprehensive Cancer Network(R) (NCCN) Guidelines
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 13 Aug 2018
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA(R) (edoxaban)
Biopharmaceuticals
 HSMN NewsFeed - 24 Jul 2018
GenomeDx Announces Medicare Draft Local Coverage Determination (LCD) for Decipher Prostate Biopsy Genomic Classifier
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2018
GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 22 Feb 2018
Varian Acquires Evinance Innovation, Inc.
Devices Oncology Mergers & Acquisitions
 HSMN NewsFeed - 20 Feb 2018
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Sep 2017
NCCN Guidelines to Include Categories of Preference
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 7 Sep 2017
Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
Diagnostics Oncology
 HSMN NewsFeed - 5 Sep 2017
Biocept Launches Liquid Biopsy Test for NRAS Mutations
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Jul 2017
NCCN Guidelines and NCCN Templates to be Integrated into ION Solutions' IntelliDoseTxM Treatment Management Module
Devices Oncology
 HSMN NewsFeed - 14 Jul 2017
Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 3 Jul 2017
New Analysis Reveals First-Line Treatment Data on SIR-Spheres(R) Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
Devices Oncology
 HSMN NewsFeed - 20 Jun 2017
NCCN Guidelines Compliance for Chest CT Reduces False Positives and Decreases Health Care Spending in Breast Cancer, Study Finds
Devices Oncology Radiology
 HSMN NewsFeed - 19 Jun 2017
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2017
Medicare Coverage of Prolaris(R) Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 May 2017
CyberKnife(R) System Provides Effective Treatment Option with Minimal Side Effects and Excellent Cosmesis for Early Stage Breast Cancer Patients
Devices Oncology
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Oct 2016
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2016
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
Devices Oncology
 HSMN NewsFeed - 11 May 2016
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 2 May 2016
Enhanced Cystoscopy including Blue Light Cystoscopy with Cysview(R)/Hexvix(R) is Recommended in the New AUA/SUO Bladder Cancer Guideline
Biopharmaceuticals Diagnostics Urology Oncology
 HSMN NewsFeed - 24 Mar 2016
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Mar 2016
ProMark(R) Prostate Cancer Prognostic Now Included in NCCN Guidelines
Diagnostics Oncology
 HSMN NewsFeed - 17 Feb 2016
Interpace Diagnostics Receives Medicare Coverage For Its ThyraMIR(TM) Micro RNA Gene Expression Classifer
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 4 Feb 2016
GenomeDx Publishes First Study Supporting Use of Decipher Test in Prostate Biopsy
Diagnostics Oncology
 HSMN NewsFeed - 12 Jan 2016
Interpace Diagnostics' New Molecular Test for Thyroid Nodules Now Available Through LabCorp
Diagnostics Oncology
 HSMN NewsFeed - 29 Jul 2015
Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 11 Jun 2015
Personal Genome Diagnostics Launches LungSelect(TM) For Non-Invasive Detection Of Clinically Actionable Mutations In Lung Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 29 May 2015
Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting
Diagnostics Oncology
 HSMN NewsFeed - 18 Feb 2015
Biodesix Builds on Investments in Sales, Reimbursement and Government Affairs Growth Strategy
Diagnostics Personnel
 HSMN NewsFeed - 3 Feb 2015
Guardant Health Secures Additional $50 Million Based On Strong Demand For Its Biopsy-Free Cancer Blood Test, Guardant360(R)
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 5 Aug 2014
Caris Molecular Intelligence(TM) Identifies Key Biomarkers of Clinical Benefit and Resistance to Chemotherapy through Multi-Technology Tumor Profiling
Diagnostics Oncology
 HSMN NewsFeed - 2 Jun 2014
Myriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
Diagnostics Oncology
 HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2014
Margaret A. Tempero, MD, Named Editor-in-Chief of JNCCN
Oncology Personnel
 HSMN NewsFeed - 12 Dec 2013
Myriad myRisk Hereditary Cancer(TM) Test Significantly Improves Detection of Women at Risk for Hereditary Cancer by 51 Percent
Diagnostics Oncology
 HSMN NewsFeed - 26 Aug 2013
Ceptaris Receives FDA Approval for VALCHLOR(TM) (mechlorethamine) Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jun 2013
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2013
Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
Diagnostics Personnel
 HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Mar 2013
Precision Therapeutics Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer using Personalized Chemotherapy Diagnostic ChemoFx(R)
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 31 Jan 2013
Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2013
New NCCN Guidelines for Patients(R) Available for Adolescents and Young Adults with Cancer
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 22 Jan 2013
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
Devices Oncology
 HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jun 2012
Caris Life Sciences Launches Caris Target Now(TM) Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary
Diagnostics Oncology
 HSMN NewsFeed - 5 Apr 2012
Richard T. Kloos, M.D., Joins Veracyte as Senior Medical Director
Diagnostics Personnel
 HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jan 2012
Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 1 Nov 2011
BSD Medical Announces Broadening of NCCN Guidelines for the Treatment of Soft Tissue Sarcoma by Hyperthermia Combined with Chemotherapy
Devices Oncology
 HSMN NewsFeed - 22 Aug 2011
FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
Diagnostics Oncology FDA
 HSMN NewsFeed - 2 Aug 2011
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
Oncology
 HSMN NewsFeed - 25 Jul 2011
St. Gallen International Breast Cancer Expert Panel Guidelines Include Oncotype DX(R) as Predictor of Chemotherapy Benefit
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2011
BSD Medical Announces the Inclusion of Hyperthermia and Chemotherapy as a Recommended Cancer Treatment for High Risk Sarcoma in the NCCN Practice Guidelines
Devices Oncology
 HSMN NewsFeed - 5 Jan 2011
Melanoma, Ovarian, and Prostate Cancer Treatment Guidelines for Patients Available from NCCN
Oncology
 HSMN NewsFeed - 9 Dec 2010
New Multiple Myeloma Treatment Guidelines for Patients Available from NCCN
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Nov 2010
BSD Medical Reports Publication of Special Edition of the International Journal of Hyperthermia Highlighting the Role of Hyperthermia in the Treatment of Breast Cancer
Devices Oncology
 HSMN NewsFeed - 16 Mar 2010
NCCN Guidelines Expand Their Reach to Japan
Oncology
 HSMN NewsFeed - 10 Mar 2010
Sam Donaldson Named Inaugural Chair of NCCN Foundation Board
Oncology Personnel
 HSMN NewsFeed - 26 Jan 2010
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2009
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2008
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2008
BSD Medical: NCCN Clinical Practice Guidelines Indicate Significantly Superior Treatment Response When Regional Hyperthermia is Added to Chemotherapy
Devices Oncology
 HSMN NewsFeed - 3 Nov 2008
NCCN Updates Guidelines for Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2008
NCCN Previews Chemotherapy Order Templates(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2008
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2008
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Mar 2008
Oncology Researcher Forecasts Increased Use of Predictive Medicine at NCCN Conference
Diagnostics Oncology
 HSMN NewsFeed - 13 Mar 2008
Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
BCBSA and NCCN Announce Strategic Collaboration
Oncology
 HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Feb 2008
NCCN Updates Ovarian Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2008
FDA Approves EMEND(R) (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Dec 2007
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Nov 2007
NCCN Updates Pancreatic Adenocarcinoma Guidelines
Oncology
 HSMN NewsFeed - 15 Nov 2007
NCCN Receives Major Grant for Anti-Cancer Drug Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Central Nervous System Cancers Guidelines
Devices Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Multiple Myeloma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Non-Small Cell Lung Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2007
JNCCN Named as Reference by CMS for Off-Label Coverage Decisions
Oncology
 HSMN NewsFeed - 26 Sep 2007
New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2007
NCCN Updates Dermatofibrosarcoma Protuberans Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2007
NCCN Updates Hepatobiliary Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2007
NCCN Updates Kidney Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2007
NCCN Updates Cervical Cancer Guidelines
Devices Oncology
 HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
NCCN Updates Thyroid Carcinoma Guidelines
Oncology
 HSMN NewsFeed - 22 May 2007
NCCN Updates Esophageal and Gastric Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2007
NCCN Updates Head and Neck Cancers Guidelines
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 22 May 2007
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2007
NCCN Updates Prevention and Treatment of Cancer-Related Infections Guidelines
Oncology
 HSMN NewsFeed - 20 Mar 2007
New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2007
Robot Spurs Men's Recovery After Surgery, Urologist Says at NCCN Annual Conference
Devices Surgery Oncology
 HSMN NewsFeed - 5 Mar 2007
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
Oncology
 HSMN NewsFeed - 26 Feb 2007
NCCN Updates Occult Primary Guidelines
Diagnostics Oncology
 HSMN NewsFeed - 26 Feb 2007
NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2007
NCCN Updates Breast Cancer Risk Reduction Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Prostate Cancer Guidelines
Devices Surgery Oncology
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Non-Small Cell Lung Cancer Guidelines
Devices Radiology Oncology
 HSMN NewsFeed - 8 Jan 2007
NCCN Updates Multiple Myeloma Guidelines
Oncology
 HSMN NewsFeed - 8 Jan 2007
NCCN Offers HER2 Testing for Breast Cancer Patients(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2007
NCCN Updates Antiemesis Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2006
Hyperthermia Therapy for Recurrent Breast Cancer Added to 2007 NCCN Guidelines
Devices Oncology
 HSMN NewsFeed - 12 Dec 2006
VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2006
Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease
Biopharmaceuticals
 HSMN NewsFeed - 18 May 2006
Large Head-to-Head Study of Aranesp(R) Dosed Every Two Weeks versus Epoetin Alfa Dosed Weekly Published in the Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2006
NCCN Announces Important Updates to Soft Tissue Sarcoma Guidelines
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 45

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 45 additional stories matching:
NCCN
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.